Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: Inhibition of the metastasis-inducer snail and induction of the metastasis-suppressor RKIP

Cell Cycle

Volumn 9, Issue 24, 2010, Pages 4931-4940

  Baritaki, Stavroula ^a   Huerta Yepez, Sara ^a,c   Sahakyan, Anna ^a   Karagiannides, Iordanis ^b   Bakirtzi, Kyriaki ^b   Jazirehi, Ali R ^a   Bonavida, Benjamin ^a   Kugel, Jennifer F ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^d NONE

Author keywords

Epithelial to mesenchymal transition (EMT); NF B; Nitric oxide; Raf 1 kinase inhibitor protein (RKIP); Snail

Indexed keywords

DETANONOATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; NITRIC OXIDE DONOR; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; SALINOSPORAMIDE A; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER CELL; CANCER INVASION; CONTROLLED STUDY; DNA BINDING; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; METASTASIS; PHENOTYPE; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION;

GASTROPODA; MUS;

EID: 78650411614     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.24.14229     Document Type: Article

References (55)

1. Wink DA, Vodovotz Y, Cook JA, Krishna MC, Kim S, Coffin D, et al. The role of nitric oxide chemistry in cancer treatment. Biochemistry (Mosc) 1998; 63:802-9.
2. Xie K, Huang S. Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. Free Radic Biol Med 2003; 34:969-86.
3. Williams EL, Djamgoz MB. Nitric oxide and metastatic cell behavior. Bioessays 2005; 27:1228-38.
4. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumor progression. Nat Rev Cancer 2006; 6:521-34.
5. Surazynski A, Liu Y, Miltyk W, Phang JM. Nitric oxide regulates prolidase activity by serine/threonine phosphorylation. J Cell Biochem 2005; 96:1086-94.
6. Yasuoka H, Kodama R, Hirokawa M, Takamura Y, Miyauchi A, Sanke T, et al. CXCR4 expression in papillary thyroid carcinoma: Induction by nitric oxide and correlation with lymph node metastasis. BMC Cancer 2008; 8:274.
7. Ivanova K, Le Poole IC, Gerzer R, Westerhof W, Das PK. Effect of nitric oxide on the adhesion of human melanocytes to extracellular matrix components. J Pathol 1997; 183:469-76.
8. Ivanova K, Lambers B, van den Wijngaard R, Le Poole IC, Grigorieva O, Gerzer R, et al. Immortalization of human melanocytes does not alter the de novo properties of nitric oxide to induce cell detachment from extracellular matrix components via cGMP. In Vitro Cell Dev Biol Anim 2008; 44:385-95.
9. Cao G, Su J, Lu W, Zhang F, Zhao G, Marteralli D, et al. Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther 2001; 8:497-505.
10. Jiang JL, Zhou Q, Yu MK, Ho LS, Chen ZN, Chan HC. The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells. J Biol Chem 2001; 276:46870-7.
11. Pipili-Synetos E, Papageorgiou A, Sakkoula E, Sotiropoulou G, Fotsis T, Karakiulakis G, et al. Inhibition of angiogenesis, tumor growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br J Pharmacol 1995; 116:1829-34.
12. Takenaga M, Igarashi R, Ochiai A, Mizushima Y. Effect of lecithinized superoxide dismutase (PC-SOD) on experimental pulmonary metastasis in mice. Free Radic Biol Med 1999; 26:1117-25.
13. Simeone AM, McMurtry V, Nieves-Alicea R, Saavedra JE, Keefer LK, Johnson MM, et al. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JSK in breast cancer cells. Breast Cancer Res 2008; 10:44.
14. Min C, Eddy SF, Sherr DH, Sonenshein GE. NFkappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem 2008; 104:733-44.
15. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009; 102:19-65.
16. Wu WS, Wu JR, Hu CT. Signal cross talks for sustained MAPK activation and cell migration: The potential role of reactive oxygen species. Cancer Metastasis Rev 2008; 27:303-14.
17. Suh J, Rabson AB. NFkappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 2004; 91:100-17.
18. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, et al. NFkappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004; 114:569-81.
19. Zhang L, Chen W, Li X. A novel anticancer effect of butein: Inhibition of invasion through the ERK1/2 and NFkappaB signaling pathways in bladder cancer cells. FEBS Lett 2008; 582:1821-8.
20. Tozawa K, Sakurada S, Kohri K, Okamoto T. Effects of anti-nuclear factor kappaB reagents in blocking adhesion of human cancer cells to vascular endothelial cells. Cancer Res 1995; 55:4162-7.
21. Shin SR, Sanchez-Velar N, Sherr DH. Sonenshein GE. 7,12-dimethylbenz(a) anthracene treatment of a c-rel mouse mammary tumor cell line induces epithelial to mesenchymal transition via activation of nuclear factor kappaB. Cancer Res 2006; 66:2570-5.
22. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene 2009; 28:3573-85.
23. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7:131-42.
24. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2:76-83.
25. Beach S, Tang H, Park S, Dhillon AS, Keller ET, Kolch W, et al. Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 2008; 27:2243-8.
26. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999; 401:173-7.
27. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, et al. Raf kinase inhibitor protein interacts with NFkappaB-inducing kinase and TAK1 and inhibits NFkappaB activation. Mol Cell Biol 2001; 21:7207-17.
28. Granovsky AE, Rosner MR. Raf kinase inhibitory protein: A signal transduction modulator and metastasis suppressor. Cell Res 2008; 18:452-7.
29. Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J, et al. Effects of Raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res 2009; 7:832-40.
30. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK. Reduction in Raf kinase inhibitor protein expression is associated with increased Rasextracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 2004; 64:5186-92.
31. Keller ET, Fu Z, Brennan M. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. J Cell Biochem 2005; 94:273-8.
32. Baritaki S, Yeung K, Palladino M, Berenson J, Bonavida B. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Res 2009; 69:8376-85.
33. l expression. Oncogene 2004; 23:4993-5003.
34. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F, et al. Activation of NFkappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 2007; 26:7445-56.
35. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: Structure, function and therapeutic implications in cancer biology. Oncogene 2006; 25:1125-42.
36. Hongo F, Garban H, Huerta-Yepez S, Jazirehi AR, Mizutani Y, Miki T, et al. Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation. Biochem Biophys Res Commun 2005; 336:692-701.
37. Santos-Silva MC, Freitas MS, Assreuy J. Involvement of NFkappaB and glutathione in cytotoxic effects of nitric oxide and taxol on human leukemia cells. Leuk Res 2006; 30:145-52.
38. Sun Y, Rigas B. The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res 2008; 68:8269-77.
39. 2- dependent activation of nuclear factor kappaB. Role in sensitization of human tumor cells to tumor necrosis factoralpha-induced cytotoxicity. J Biol Chem 2001; 276:8918-23.
40. Park SW, Wei LN. Regulation of c-myc gene by nitric oxide via inactivating NFkappaB complex in P19 mouse embryonal carcinoma cells. J Biol Chem 2003; 278:29776-82.
41. Watanabe M, Dewan MZ, Okamura T, Sasaki M, Itoh K, Higashihara M, et al. A novel NFkappaB inhibitor DHMEQ selectively targets constitutive NFkappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer 2005; 114:32-8.
42. Huerta-Yepez S, Vega M, Escoto-Chavez SE, Murdock B, Sakai T, Baritaki S, et al. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide 2009; 20:39-52.
43. L in Fas resistance and chemoresistance, respectively. J Immunol 2005; 175:2174-83.
44. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumor cells. Nat Cell Biol 2002; 2:84-9.
45. Yang MH, Chang SY, Chiou SH, Liu CJ, Chi CW, Chen PM, et al. Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. Oncogene 2007; 26:1459-67.
46. Olmeda D, Jorda M, Peinado H, Fabra A, Cano A. Snail silencing effectively suppresses tumor growth and invasiveness. Oncogene 2007; 26:1862-74.
47. Tsao DA, Yu HS, Chang HR. Nitric oxide enhances expression of raf kinase inhibitor protein in keratinocytes. Exp Dermatol 2009; 18:571-3.
48. Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J 2009; 28:347-58.
49. Rigas B. Novel agents for cancer prevention based on nitric oxide. Biochem Soc Trans 2007; 35:1364-8.
50. Morley D, Keefer LK. Nitric oxide/nucleophile complexes: A unique class of nitric oxide-based vasodilators. J Cardiovasc Pharmacol 1993; 22:3-9.
51. Miller MR, Megson IL. Recent developments in nitric oxide donor drugs. Br J Pharmacol 2007; 151:305-21.
52. Diodati JG, Quyyumi AA, Hussain N, Keefer LK. Complexes of nitric oxide with nucleophiles as agents for the controlled biological release of nitric oxide: antiplatelet effect. Thromb Haemost 1993; 70:654-8.
53. Nielsen VG. Nitric oxide decreases coagulation protein function in rabbits as assessed by thromboelastography. Anesth Analg 2001; 92:320-3.
54. Wink DA, Ridnour LA, Hussain SP, Harris CC. The reemergence of nitric oxide and cancer. Nitric Oxide 2008; 19:65-7.
55. Baritaki S, Katsman A, Chatterjee D, Yeung KC, Spandidos DA, Bonavida B. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 upregulation. J Immunol 2007; 179:5441-53.